Sab Biotherapeutics, INC Form 4 insider transactions

Director Jeffrey G. Spragens receives a stock option grant for 20,000 shares of SAB Biotherapeutics, Inc.

Director William James Polvino received stock option grants from SAB Biotherapeutics, Inc. on July 15, 2024, as part of his compensation as a board member.

Director Jay S. Skyler receives stock options as part of annual and inaugural grants for board service.

Eddie Joe Sullivan, a director and President of SAB Biotherapeutics, reported the acquisition of stock options on July 15, 2024.

Director Erick Lucera reports acquisition of 20,000 stock options in SAB Biotherapeutics, Inc. as part of the annual board grant.

Christine E. Hamilton, a director of SAB Biotherapeutics, received multiple stock option grants on July 15, 2024, as part of her compensation and for her spouse's advisory role.

Director David Charles Link acquired stock options in SAB Biotherapeutics, Inc. as part of his annual board grant and a one-time grant.

Samuel Reich, CEO and Executive Chairman of SAB Biotherapeutics, acquired stock options for 35,700 shares on July 15, 2024.

Scott Giberson, a director of SAB Biotherapeutics, acquired 20,000 stock options on July 15, 2024, as part of the annual grant for board members.